The Journal of Clinical Nuclear Medicine has published results from a study of Tiziana Life Sciences’ nasal Foralumab. The study tested the drug in patients with moderate Alzheimer’s disease.
Researchers gave one patient daily doses of nasal Foralumab for 13 weeks. They followed this with a 13-week treatment-free period. The patient showed reduced brain inflammation and improved brain activity. These improvements were visible on PET scans and EEG readings.
The treatment lowered signals linked to microglial activation. Microglia are brain cells involved in inflammation. The EEG data also showed improved brain wave patterns. These patterns are often disrupted in people with Alzheimer’s disease.
Dr. Howard L. Weiner, a co-director at the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital, led the study. He said the findings support nasal Foralumab as a new way to treat brain inflammation in Alzheimer’s disease. Dr. Weiner emphasized the need for therapies that target inflammation in the brain.
Tiziana Life Sciences is now preparing for a larger Phase 2 clinical trial. This trial will include more patients and will further test the safety and effect of nasal Foralumab.
Nasal Foralumab is a fully human monoclonal antibody. It is the only clinical-stage anti-CD3 therapy delivered through the nose. The goal of this method is to reduce inflammation without weakening the immune system.
The U.S. Food and Drug Administration (FDA) previously granted approval for Tiziana to move forward with its expanded trial. This approval followed positive results in other early-stage studies.
Tiziana CEO Gabriele Cerrone said the company is committed to advancing nasal Foralumab. He stated that the data marks a step forward in treating Alzheimer’s disease using a non-invasive method.
Foralumab has also shown promise in other conditions, including multiple sclerosis and COVID-19. These results suggest the drug’s broader potential in diseases where inflammation plays a key role.
Tiziana Life Sciences continues to study nasal Foralumab’s effects. The company plans to expand research efforts based on these latest findings.
